AyuVis Granted FDA Approval for Human Trials of Immunotherapy AVR-48 in Inflammation and Infection

Written By Kathleen Otto

AyuVis Research, Inc., a clinical-stage biopharmaceutical company focusing on immunotherapies for inflammation and infection, has received FDA approval to commence human clinical trials for its lead compound, AVR-48. The company aims to develop immunotherapies that offer a well-balanced immune response, combining mild activation and controlled suppression for effective disease treatment.

Dr. Suchi Acharya, AyuVis co-founder and CEO, expresses excitement about the Investigational New Drug (IND) approval, considering it a major milestone for the company's small molecule immunotherapy platform program.

Kathleen Otto
Previous

Liviniti Partners with Mark Cuban's Cost Plus Drug Company to Enhance Prescription Savings
Next

Nanoscope's MCO-010 Gene Therapy Progresses with FDA Support for Retinitis Pigmentosa Treatment